EssilorLuxottica Reports Record Growth of 11.2% in 2025, Exceeding 28 Billion Euros in Revenue
EssilorLuxottica concluded the 2025 fiscal year with a marked acceleration, achieving an annual revenue of 28,491 million euros, up by 11.2% at constant exchange rates. The fourth quarter saw even more dynamic growth at 18.4%, driven by the demand for artificial intelligence-enabled glasses and the group's geographic expansion.
Annual Performance and Product Highlights
EssilorLuxottica achieved an annual revenue of 28,491 million euros in 2025, marking an 11.2% increase at constant exchange rates. The fourth quarter experienced a significant acceleration with a record 18.4% increase. This performance occurred amidst ongoing macroeconomic and geopolitical tensions, as well as the impact of U.S. tariffs. All geographic regions, including North America, the EMEA zone, and Asia-Pacific, recorded double-digit growth both in the fourth quarter and for the full year. In terms of products, glasses equipped with artificial intelligence sold over 7 million units during the year, benefiting from a balanced contribution across all regions and brands in the portfolio. The newly launched Nuance Audio glasses, introduced as a new category, had a promising first year and are now distributed in 12 countries and available in 15,000 retail outlets worldwide. The portfolio of myopia management solutions also saw significant expansion with a 22% revenue growth globally, with a strengthened position in the U.S. for a solid start.
Financial Metrics and Shareholder Returns
The adjusted operating margin stood at 16.0% for the fiscal year 2025 at constant exchange rates, affected by U.S. tariffs and investments in artificial intelligence glasses. Free cash flow reached a record level of 2.8 billion euros for the year, representing an increase of 400 million euros compared to 2024. EssilorLuxottica is offering a dividend of 4.00 euros per share, with an option for shareholders to receive payment in shares. The board of directors finalized the consolidated accounts on February 11, 2026, and validated an update of the long-term outlook initially communicated in March 2022.
Future Outlook and Strategic Transformation
Over the next five years and at constant exchange rates, the group anticipates solid growth in total revenue, accompanied by a generally aligned increase in adjusted operating income. This trajectory is part of the transformation towards the medtech sector, which the group confirms it is resolutely pursuing. The management expresses confidence in the continuation of this growth dynamic, based on the robustness and relevance of its strategic vision and the excellence of its operational execution.
